Baseline demographics of TCZ monotherapy patients who transitioned to LTE. Values are mean (SD) unless otherwise specified.
| Demographic | TCZ Monotherapy, n = 134 |
|---|---|
| Age, yrs | 51.1 (12.3) |
| Female, n (%) | 111 (82.8) |
| Baseline oral corticosteroid use, n (%) | 60 (44.8) |
| No. previous DMARD | 0.9 (1.0) |
| No. previous anti-TNF | 0.1 (0.3) |
| RA duration, yrs | 5.9 (7.4) |
| CRP, mg/dl | 3.0 (3.3) |
| ESR, mm/h | 51.3 (26.0) |
| TJC68 | 32.3 (14.3) |
| SJC66 | 18.7 (9.9) |
| VAS PtGA, mm* | 62.5 (19.2) |
| DAS28* | 6.8 (0.9) |
↵* n = 133. TCZ: tocilizumab; LTE: longterm extension; DMARD: disease-modifying antirheumatic drug; anti-TNF: antitumor necrosis factor; RA: rheumatoid arthritis; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; TJC68: tender joint count at 68 joints; SJC66: swollen joint count at 66 joints; VAS: visual analog scale; PtGA: patient’s global assessment; DAS28: Disease Activity Score at 28 joints.